Nabiximols

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564342

CAS#: 56575-23-6

Description: Nabiximols is a delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) combination for the treatment of multiple sclerosis (MS) related moderate to severe spasticity.


Price and Availability

Size
Price

Size
Price

Size
Price

Nabiximols is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 564342
Name: Nabiximols
CAS#: 56575-23-6
Chemical Formula: C42H60O4
Exact Mass: 628.4492
Molecular Weight: 628.94
Elemental Analysis: C, 80.21; H, 9.62; O, 10.18


Synonym: GW1000; GW 1000; GW-1000; SAB-378; SAB 378; SAB378; Sativex; Nabiximols

IUPAC/Chemical Name: (6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol

InChi Key: SSNHGLKFJISNTR-FWUPRJFYSA-N

InChi Code: InChI=1S/2C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15;1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,16-17,22H,5-10H2,1-4H3;11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t16-,17-;17-,18?/m10/s1

SMILES Code: OC1=CC(CCCCC)=CC2=C1[C@@](C=C(C)CC3)([H])[C@]3([H])C(C)(C)O2.OC4=CC(CCCCC)=CC(O)=C4C5C=C(C)CC[C@H]5C(C)=C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Sorosina M, Clarelli F, Ferrè L, Osiceanu AM, Unal NT, Mascia E, Martinelli V, Comi G, Benigni F, Esposito F, Martinelli Boneschi F. Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16. PubMed PMID: 29528549.

2: Bhardwaj AK, Allsop DJ, Copeland J, McGregor IS, Dunlop A, Shanahan M, Bruno R, Phung N, Montebello M, Sadler C, Gugusheff J, Jackson M, Luksza J, Lintzeris N; Agonist Replacement for Cannabis Dependence (ARCD) study group. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. BMC Psychiatry. 2018 May 18;18(1):140. doi: 10.1186/s12888-018-1682-2. PubMed PMID: 29776349; PubMed Central PMCID: PMC5960200.

3: Castelli L, Prosperini L, Pozzilli C. Balance worsening associated with nabiximols in multiple sclerosis. Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649. [Epub ahead of print] PubMed PMID: 29533137.

4: Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Kornyeyeva E, Fallon MT. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. J Pain Symptom Manage. 2018 Feb;55(2):179-188.e1. doi: 10.1016/j.jpainsymman.2017.09.001. Epub 2017 Sep 18. PubMed PMID: 28923526.

5: Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, Barnes AJ, Huestis MA, George TP, Streiner DL, Staios G, Le Foll B. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS One. 2018 Jan 31;13(1):e0190768. doi: 10.1371/journal.pone.0190768. eCollection 2018. PubMed PMID: 29385147; PubMed Central PMCID: PMC5791962.

6: Kanaan AS, Jakubovski E, Müller-Vahl K. Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. Brain Sci. 2017 Apr 26;7(5). pii: E47. doi: 10.3390/brainsci7050047. PubMed PMID: 28445405; PubMed Central PMCID: PMC5447929.